ClinicalTrials.gov
ClinicalTrials.gov Menu

Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00510432
Recruitment Status : Unknown
Verified August 2009 by Johann Wolfgang Goethe University Hospital.
Recruitment status was:  Recruiting
First Posted : August 2, 2007
Last Update Posted : August 19, 2009
Sponsor:
Information provided by:
Johann Wolfgang Goethe University Hospital

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

An increased number of patients with heparin-induced skin lesions is reported in the literature. Heparin-induced skin lesions may result from either occlusion of cutaneous vessels in patients suffering from autoimmune HIT or from a type IV allergic reaction (delayed type hypersensitivity (DTH) response). However, the incidence and nature of heparin-induced skin lesions has not been determined in a prospective investigation.

To address this open issue is the goal of this ongoing, so far monocenter, clinical investigation.


Condition or disease
Allergy

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Inzidenz Und Art Heparin-induzierter Hautveränderungen
Study Start Date : April 2007
Estimated Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
s.c. anticoagulant therapy
All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients receiving s.c. anti-coagulation
Criteria

Inclusion Criteria:

  • age > 18 Y.
  • s.c. anticoagulant therapy >6 days

Exclusion Criteria:

  • history of HIT
  • history of DTH to heparin
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00510432


Contacts
Contact: Ralf J Ludwig, MD +49-69-6301- ext 6162 r.ludwig@em.uni-frankfurt.de
Contact: Wolf-Henning Boehncke, Professor +49-69-6301- ext 5143 boehncke@em.uni-frankfurt.de

Locations
Germany
Department of Dermatology - Clinic of the Johann Wolfgang Goethe University Recruiting
Frankfurt am Main, Hessen, Germany, 60590
Contact: Ralf J Ludwig, MD    +49-69-6301- ext 6162    r.ludwig@em.uni-frankfurt.de   
Contact: Marc Schindewolf, MD    +49-69-6301- ext 5444    marcschindewolf@yahoo.com   
Principal Investigator: Ralf J Ludwig, MD         
Sub-Investigator: Marc Schindewolf, MD         
Sub-Investigator: Svantje Schwaner, MD         
Sub-Investigator: Edelgard Lindhoff-Last, PD         
Sub-Investigator: Wolf-Henning Boehncke, Prof         
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Investigators
Principal Investigator: Ralf J Ludwig, MD Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
Homepage of the Department of Dermatology with contact persons in the dermatology department listed (site in German)  This link exits the ClinicalTrials.gov site
Homepage of the Department of Internal Medicine (Angiology) with contact persons in the angiology department listed (site in German)  This link exits the ClinicalTrials.gov site

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Dr. Marc Schindewolf, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT00510432     History of Changes
Other Study ID Numbers: 16/07
First Posted: August 2, 2007    Key Record Dates
Last Update Posted: August 19, 2009
Last Verified: August 2009

Keywords provided by Johann Wolfgang Goethe University Hospital:
heparin
heparin-induced thrombocytopenia
HIT
allergy
skin
dermatology
 DTH
delayed-type hypersensitivity
histology
Patients receiving sc heparin therapy
Age over 18 years
Recruitment will stop when 20 patients with skin lesions are included

Additional relevant MeSH terms:
Calcium heparin
Heparin
Anticoagulants
 Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action